Top Page
RemeGen Co. Ltd. Class H
(9995)
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
RemeGen Co. Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.07B | 1.72B | 1.08B | 767.77M | 1.42B | 0.00 |
| Gross Profit | 1.72B | 1.37B | 822.99M | 497.84M | 1.36B | 0.00 |
| EBITDA | -839.66M | -1.19B | -1.25B | -805.70M | 402.05M | -661.56M |
| Net Income | -1.14B | -1.47B | -1.51B | -997.84M | 276.26M | -727.09M |
Balance Sheet | ||||||
| Total Assets | 5.85B | 5.50B | 5.53B | 6.02B | 4.16B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 1.28B | 759.53M | 709.07M | 2.19B | 1.76B | 2.77B |
| Total Debt | 2.67B | 2.67B | 1.26B | 165.03M | 102.78M | 197.69M |
| Total Liabilities | 3.49B | 3.51B | 2.09B | 1.04B | 712.79M | 523.07M |
| Stockholders Equity | 2.36B | 1.99B | 3.44B | 4.98B | 3.45B | 3.59B |
Cash Flow | ||||||
| Free Cash Flow | -783.71M | -1.38B | -2.35B | -2.02B | -353.71M | -1.14B |
| Operating Cash Flow | -539.67M | -1.11B | -1.50B | -1.26B | 263.63M | -660.08M |
| Investing Cash Flow | -32.71M | -248.24M | -817.65M | -841.56M | -637.95M | -479.06M |
| Financing Cash Flow | 1.17B | 1.39B | 978.31M | 2.43B | -626.90M | 3.90B |
RemeGen Co. Ltd. Class H Technical Analysis
RemeGen Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$38.94B | 43.75 | 27.37% | ― | 2.57% | 18.79% | |
| ― | $34.82B | ― | ― | ― | ― | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$38.08B | -21.94 | -15.06% | ― | 39.02% | 48.26% | |
| ― | HK$22.73B | ― | -29.51% | ― | 32.07% | 33.55% | |
| ― | HK$52.13B | -37.14 | -45.12% | ― | 47.62% | 28.72% |
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Co., Ltd. has released its unaudited 2025 third quarterly report, prepared according to Chinese accounting principles and the STAR Market requirements of the Shanghai Stock Exchange. The report, which has been reviewed by the audit committee but not by independent auditors, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, advising shareholders and potential investors to exercise caution when dealing with its securities.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced the renewal of several connected transactions, including the MabPlex Master Service Agreement and the Materials Purchase Framework Agreement, extending their terms from 2026 to 2028. These transactions, which involve key stakeholders such as MabPlex and RC Pharma, are crucial for the company’s continued operations and strategic partnerships. Additionally, the company plans to adjust its leasing agreements by increasing equipment leases and reducing building and apartment leases, reflecting its business expansion and changing demand.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced that its board of directors will convene on October 30, 2025, to review and approve the company’s unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$89.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced a discloseable transaction involving the purchase of wealth management products from SPDB Yantai Branch, utilizing idle self-owned funds and raised proceeds. The transaction involves a total investment of RMB500 million, with the aim of optimizing cash management and potentially enhancing financial returns through principal-guaranteed products linked to the EUR-USD exchange rate. This move is subject to reporting and announcement requirements under the Hong Kong Listing Rules, reflecting the company’s strategic financial management efforts.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$89.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd., a joint stock company incorporated in the People’s Republic of China, has announced a discloseable transaction involving the purchase of a wealth management product. The company has decided to utilize RMB300.0 million of its idle self-owned funds to purchase a principal-guaranteed bank wealth management product from SPDB Yantai Branch. This transaction, along with previous similar agreements with SPDB, is considered a discloseable transaction under the Listing Rules due to the aggregated percentage ratios exceeding 5%. This move is part of the company’s cash management strategy and reflects its approach to managing idle funds.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$73.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced that its drug, Telitacicept, has successfully met the primary endpoint in Stage A of a Phase III clinical trial for treating IgA Nephropathy in China. This achievement marks a significant step forward for the company as it plans to submit a Biologics License Application to the National Medical Products Administration of China. The trial demonstrated a 55% reduction in the 24-hour urine protein-to-creatinine ratio, indicating the drug’s potential efficacy and safety. This development could position RemeGen as a key player in addressing the unmet medical need for novel IgAN therapeutics, potentially impacting the chronic kidney disease market.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$59.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced amendments to its Articles of Association following the placement of 19,000,000 new H Shares, which resulted in an increase in the company’s registered capital. The amendments, approved by the Board on August 22, 2025, reflect changes in the shareholding structure and authorize the management to carry out necessary procedures in compliance with domestic and international requirements. This strategic move is expected to enhance RemeGen’s operational capabilities and strengthen its market position.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$59.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. reported a significant increase in revenue for the first half of 2025, driven by strong sales of its key products, telitacicept and disitamab vedotin. The company achieved several milestones, including the approval of telitacicept for generalized myasthenia gravis in China and its designation as an Orphan Drug in Europe. Disitamab vedotin also received marketing approval in China for HER2-positive advanced breast cancer, marking a substantial advancement in their product pipeline. These developments are likely to enhance RemeGen’s market position and offer promising implications for stakeholders.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$59.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced that its novel bispecific antibody, RC148, has been granted Breakthrough Therapy Designation by the China National Medical Products Administration for the treatment of non-small cell lung cancer (NSCLC). This designation, based on promising Phase I/II clinical study results, will expedite the development and potential market approval of RC148, highlighting its significant clinical value and offering a new treatment option for patients with advanced NSCLC who have failed prior therapies.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has entered into a licensing agreement with Santen Pharmaceutical (China) Co., Ltd., granting Santen China exclusive rights to develop, manufacture, and commercialize the RC28-E Injection in Greater China and several Southeast Asian countries. This agreement, which includes significant upfront, milestone, and sales payments, is expected to accelerate market access for RC28-E, enhancing patient coverage and shortening its commercialization cycle. The collaboration is seen as beneficial for RemeGen’s shareholders and aligns with the company’s strategic interests.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced that its drug Telitacicept met the primary endpoint in a Phase III clinical trial for primary Sjögren’s syndrome in China. This marks a significant milestone as Telitacicept is the first BLyS/APRIL dual-target fusion protein drug to complete such a study in this field. The trial demonstrated the drug’s efficacy and safety, addressing a significant unmet clinical need in Sjögren’s syndrome treatment. The company plans to submit a Biologics License Application to the National Medical Products Administration of China and present the data at international conferences. Telitacicept has also been recommended by multiple guidelines in China and has received fast track designation from the U.S. FDA for its Sjögren’s syndrome indication.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced the purchase of a principal-guaranteed wealth management product worth RMB350.0 million from CMB Yantai Branch, using idle self-owned funds. This transaction, approved by the Board, is considered a discloseable transaction under Hong Kong’s Listing Rules, reflecting the company’s strategic cash management approach to optimize returns on its idle funds.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced a board meeting scheduled for August 22, 2025, to review and approve the interim financial results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.